Steroid Hormones: Overview and Medical Applications

January 2016 in “ Elsevier eBooks ”

Ruben Vardanyan, Victor J. Hruby

From the encyclopedia

Frontline, gold standard treatment for combatting androgenic alopecia

Heavy duty finasteride that comes with higher risks

Studysummary This article discusses the various roles of steroids in vertebrate organ systems and notes several glucocorticoids that were among the Top 200 Drugs by sales in the 2010s, but it reports no new clinical findings.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on doi.org →

Discuss this study in the Community →

Research cited in this study

19 / 19 results

research Dutasteride for the Treatment of Benign Prostatic Hyperplasia

24 citations , June 2013 in “Expert opinion on pharmacotherapy”

This review found dutasteride to be effective, safe, and well-tolerated for treating symptomatic BPH and provides expert commentary on its use, though the relationship with high-grade prostate cancer remains unclear.

research A Review on Steroidal 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia

17 citations , August 2011 in “Current Medicinal Chemistry”

This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.

research An Overview on 5α-Reductase Inhibitors

219 citations , October 2009 in “Steroids”

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.

research Finasteride for Prostatic Disease: An Updated and Comprehensive Review

14 citations , November 2008 in “Expert opinion on drug metabolism & toxicology”

This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.

research Pharmacology of Anabolic Steroids

441 citations , May 2008 in “British Journal of Pharmacology”

This article reviews the potential clinical use of anabolic steroids in treating muscle loss from chronic diseases and aging and highlights both the benefits and risks of these substances in sports.

research Dutasteride

45 citations , January 2008 in “Drugs”

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

research Discovery and Clinical Development of Dutasteride, a Potent Dual 5α-Reductase Inhibitor

58 citations , March 2006 in “Current topics in medicinal chemistry”

This review describes how dutasteride, a dual 5alpha-reductase inhibitor, has improved outcomes in benign prostatic hyperplasia and is being studied for prostate cancer prevention, without new data reported.

research A New Look at the 5-Alpha-Reductase Inhibitor Finasteride

137 citations , March 2006 in “Cns Drug Reviews”

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

research Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia

52 citations , February 2006 in “Current pharmaceutical design”

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

research Recent Advances in the Chemistry and Pharmacological Activity of New Steroidal Antiandrogens and 5α-Reductase Inhibitors

20 citations , March 2005 in “Current Medicinal Chemistry”

This study reports that newly synthesized steroidal trienones exhibit higher 5α-reductase inhibitory activity than dienones in various biological models, suggesting potential use in treating androgen-dependent diseases.

research Pharmacology of Different Progestogens: The Special Case of Drospirenone

104 citations , January 2005 in “Climacteric”

This review discusses the pharmacological properties of progestins used in contraception and hormone replacement therapy, focusing on drospirenone's unique effects, but reports no new experimental findings.

research An Update on the Use of 5-Alpha-Reductase Inhibitors

7 citations , January 2004 in “Drugs of today”

This review discusses the established efficacy and safety of finasteride and dutasteride for benign prostatic hyperplasia, their use with alpha adrenergic blockers, and the potential unclear role in cancer prevention.

research Steroid 5α-Reductase Inhibitors

42 citations , May 2003 in “Mini-reviews in Medicinal Chemistry”

This study found that newly synthesized steroidal trienones demonstrated stronger 5α-reductase inhibitory activity compared to dienones in various biological models, suggesting potential for developing enhanced antiandrogenic drugs.

research Novel Inhibitors of 5α-Reductase

20 citations , February 2002 in “Expert Opinion on Therapeutic Patents”

This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.

research 5α-Reductase Inhibitors: Progress and Therapeutic Potential

5 citations , January 2001 in “Advances in protein chemistry”

This chapter reviews recent advances in 5α-reductase inhibitors for treating disorders mediated by dihydrotestosterone and reports no new clinical findings.

research Androgen Receptor Antagonists Structure-Activity Relationships

204 citations , February 2000 in “Current Medicinal Chemistry”

This review discusses the use of antiandrogens like flutamide and its derivatives in prostate cancer treatment and highlights the need for next-generation antiandrogens for improved efficacy; it reports no new clinical results.

research Dihydrotestosterone and the Concept of 5-Alpha-Reductase Inhibition in Human Benign Prostatic Hyperplasia

184 citations , January 2000 in “European Urology”

This abstract reviews the role of finasteride and potential dual 5alpha-reductase inhibitors in treating benign prostatic hyperplasia, suggesting that dual inhibitors may offer greater DHT suppression and therapeutic advantages, while emphasizing the need for clinical evaluation.

research Finasteride

40 citations , April 1999 in “Drugs”

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

research Finasteride

125 citations , January 1999 in “Drugs”

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.